Eosinophilic asthma is a type in which a higher count of white blood cells is present in the patient’s body. Some of the symptoms found in the patient include chronic rhinosinusitis, chest tightness, and breathing difficulty. As biological agents and modern medicines become more widely available, the demand for phenotype-specific treatment regimens is growing steadily. Individual allergy susceptibility has increased, leading to a rise in the cases of eosinophilic asthma.
Approximately 10% of the US population has asthma, and despite high-dose inhaled corticosteroids and long-acting beta-agonists, about 10%–20% of those individuals remain poorly managed. Berry et al. conducted a study on people with mild to moderate asthma and divided them into two groups based on whether or not they had eosinophils in their sputum. The study concluded that people with eosinophilia had a better short-term response to inhaled corticosteroids.
Report Key Takeaways
Different types of treatments and drugs are recommended for patients depending on the stage and condition of asthma.
These are maintenance medications that help you maintain regular breathing and keep asthma symptoms under control. In addition, they prevent particular cells in the lungs and airways from releasing substances that trigger asthma attacks.
Leukotrienes are substances produced by your immune system that induce asthma symptoms. Eosinophils enjoy collaborating with leukotrienes to inflame your upper and lower airways. Leukotriene modifiers, such as zafirlukast (Accolate) and montelukast (Singulair), are effective in reducing the effects of leukotrienes and helping to alleviate asthma symptoms. However, some people experience anxiety and agitation while taking these medications.
These drugs are created in a lab to mimic human antibodies. Shots or IV infusions are used instead of inhalers or pills. The role of such medications is to prevent the substances in your lungs from causing any inflammation. Soreness at the injection site is one of the side effects.
Recent Developments Related to Eosinophilic Asthma
- The FDA approved the Nucala, a prefilled pen, and a prefilled syringe for self-injection at the beginning of 2022. These newly approved versions allow subcutaneous self-injection in patients with severe eosinophilic asthma aged 12 years or older. Children aged between 6 and 11 years can be given Nucala under the observation of a healthcare practitioner.
- Upstream Bio, the US-based biotech company, purchased UPB-101 from Astellas, a Japanese pharmaceutical firm, right after completing the first clinical and preclinical research. Upstream has chosen asthma as the initial ailment to study using UPB-101, intending to look into other diseases caused by TSLP-mediated inflammation.
Major Players Working on Eosinophilic Asthma
Some major players operating in the research and development related to the eosinophilic asthma industry include Roche, Sanofi, Novartis, Johnson & Johnson, Merck, Pfizer, AstraZeneca, and Bayer. A comprehensive examination of these major companies covering their key strategies, recent developments, and plans is discussed in the pipeline insight.
Key Reasons to Purchase This Report
- The research is a compilation of multi-level analysis that gives market size, share, dynamics, and forecasts for numerous segments and sub-segments while considering the macro and micro environmental aspects.
- The pipeline insights section examines pipeline therapeutics developed by firms and research institutes using data obtained from corporate and industry-specific sources.
- To gain a broad overview of the modern pharmaceuticals in the R&D pipeline and gain a deep insight into the existing pipeline goods market.
- To access an in-depth evaluation of the therapeutic drugs, including acquisitions, collaborations, partnerships, and licensing activities, in the industry.
- An in-depth examination of the market’s leading companies, considering both existing and emerging competitors and their geographic and business areas.